Lapachol and lapachone analogs: a journey of two decades of patent research(1997-2016)

References

• Nepomuceno JC. Lapachol and its derivatives as potential drugs for cancer treatment. In Breeding and Genetic Engineering: The Biology and Biotechnology Research. iConcept Press, Kowloon, Hong Kong; 2016, pp. 1-19.
   Google Scholar
• Paterno E. Ricerche sull’acido lapachico. Gazz Chim It. 1882;12:337–392.
   Google Scholar
• Rao KV, McBride TJ, Oleson JJ. Recognition and evaluation of lapachol as an antitumor agent. Cancer Res. 1968;28:1952–1954.
   Web of Science ®Google Scholar
• Block JB, Serpick AA, Miller W, et al. Early clinical studies with lapachol (NSC-11905). Cancer Chemother Rep. 1974;4:27–28.
   Google Scholar
• Santana CF, Lins LJP, Asfora JJ, et al. Primeiras observações com o emprego de lapachol em pacientes humanos portadores de neoplasias malignas. Rev Inst Antibiot. 1980;20:61–68.
   Google Scholar
• Hussain H, Krohn K, Ahmad VU, et al. Lapachol: an overview. Arkivoc. 2007;145–171.
   Web of Science ®Google Scholar
• Fiorito S, Epifano F, Bruyère C, et al. Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives. Bioorg Med Chem Lett. 2014;24:454–457.
   PubMed Web of Science ®Google Scholar
• Epifano F, Genovese S, Fiorito S, et al. Lapachol and its congeners as anticancer agents: a review. Phytochem Rev. 2014;13:37–49.
   Web of Science ®Google Scholar
• Oliveira MF, Lemos TLG, Mattos MCD, et al. New enamine derivatives of lapachol and biological activity. An Acad Bras Cie. 2002;74:211–221.
   PubMed Web of Science ®Google Scholar
• Castellanos JRG, Prieto JM, Heinrich M. Red Lapacho (Tabebuia impetiginosa)-A global ethnopharmacological commodity? J Ethnopharmacol. 2009;121:1–13.
   PubMed Web of Science ®Google Scholar
• Medeiros CS, Pontes-Filho NT, Camara CA, et al. Antifungal activity of the naphthoquinone β-lapachone against disseminated infection with Cryptococcus neoformans var. neoformans in dexamethasone-immunosuppressed Swiss mice. Braz J Med Biol Res. 2010;43:345–349.
   PubMed Web of Science ®Google Scholar
• Moon DO, Choi YH, Kim ND, et al. Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol. 2007;7:506–514.
   PubMed Web of Science ®Google Scholar
• Terai K, Dong GZ, Oh ET, et al. Cisplatin enhances the anticancer effect of beta- lapachone by upregulating NQO1. Anticancer Drugs. 2009;20:901–909.
   PubMed Web of Science ®Google Scholar
• Guiraud P, Steiman R, Campos-Takaki GM, et al. Comparison of antibacterial and antifungal activities of lapachol and beta-lapachone. Planta Med. 1994;60:373–374.
   PubMed Web of Science ®Google Scholar
• Kung HN, Chien CL, Chau GY, et al. Involvement of NO/cGMP signaling in the apoptotic and anti-angiogenic effects of β-lapachone on endothelial cells in vitro. J Cell Physiol. 2007;211:522–532.
   PubMed Web of Science ®Google Scholar
• Sun X, Li Y, Li W, et al. Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway. Cell Cycle. 2006;5:2029–2035.
   PubMed Web of Science ®Google Scholar
• Li CJ, Li YZ, Pinto AV, et al. Potent inhibition of tumor survival in vivo by beta- lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA. 1999;96:13369–13374.
   PubMed Web of Science ®Google Scholar
• Souza-Silva F, Nascimento SB, Bourguignon SC, et al. Evidences for leishmanicidal activity of the naphthoquinone derivative epoxy-α-lapachone. Exp Parasitol. 2014;147:81–84.
   PubMed Web of Science ®Google Scholar
• Heinrich M. Roter Lapacho-Tee. Zeitschrift Für Phytotherapie. 1998;19:99–100.
   Google Scholar
• Goncalves AM, Vasconcellos ME, Docampo R, et al. Evaluation of the toxicity of 3- allyl-β-lapachone against Trypanosoma cruzi bloodstream forms. Mol Biochem Parasitol. 1980;1:167–176.
   PubMed Web of Science ®Google Scholar
• Anesisni C, Pérez C. Screening of plants used in Argentine folk medicine for antimicrobial activity. J Ethnopharmacol. 1993;39:119–128.
   PubMed Web of Science ®Google Scholar
• Guiraud P, Steiman R, Campos-Takaki GM, et al. Comparison of antibacterial and antifungal activities of lapachol and β-lapachone. Planta Med. 1994;6:373–374.
   Web of Science ®Google Scholar
• Mans DRA, Da Rocha AB, Schwartsmann G. Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anticancer compounds. The Oncologist. 2000;5:185–198.
   PubMedGoogle Scholar
• Portillo A, Vila R, Freixa B, et al. Antifungal activity of Paraguayan plants used in traditional medicine. J Ethnopharmacol. 2001;76:93–98.
   PubMed Web of Science ®Google Scholar
• Dos Santos EVM, Carneiro JWM, Ferreira VF, et al. Quantitative structure-activity relationship in aziridinyl-1,4-naphthoquinone antimalarials: study of theoretical correlations by the PM3 method. Bioorg Med Chem. 2004;12:87–93.
   PubMed Web of Science ®Google Scholar
• Cragg GM, Newman DJ. Plants as a source of anticancer agents. J Ethnopharmacol. 2005;100:72–79.
   PubMed Web of Science ®Google Scholar
• Boothman DA, Greer S, Pardee AB. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dyhydro-2,2-dimethyl- 2H-naphtol[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res. 1987;47:5361–5366.
   PubMed Web of Science ®Google Scholar
• Li CJ, Wang C, Pardee AB. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res. 1995;55:3712–3715.
   PubMed Web of Science ®Google Scholar
• Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumour cells by beta-lapachone, an activator of topoisomerase I. Cancer Res. 1989;49:605–612.
   PubMed Web of Science ®Google Scholar
• Wuerzberger S, Pink JJ, Planchon SM. Induction of apoptosis in MCF-7: WS8 breast cancer cells by beta-lapachone. Cancer Res. 1998;58:1876–1885.
   PubMed Web of Science ®Google Scholar
• Simamura E, Hirai KI, Shimada H, et al. Mitochondrial damage prior to apoptosis in furanonaphthoquinone treated lung cancer cells. Cancer Detect Prev. 2003;27:5–13.
   PubMedGoogle Scholar
• Orth H. Isolation of extraneous materials from Tabebuia flavescens by extraction. Holzforsch. 1960;14:89–91.
   Google Scholar
• Manners GD, Jurd L. A new naphthoquinone from Tabebuia guayacan. Phytochemistry. 1976;15:225–226.
   Web of Science ®Google Scholar
• Singh P, Khandelwai P, Sharma K, et al. Cetyl triacontanoate and other constituents from Acacia jacquemontii and Kigelia pinnata. J Ind Chem Soc. 2010;87:1403–1407.
   Web of Science ®Google Scholar
• Joshi KC, Prakash L, Singh P. Quinones and other constituents from Phyllarthron comorense. Phytochemistry. 1973;12:469–470.
   Web of Science ®Google Scholar
• Inoue K, Chen CC, Inouye H, et al. Quinones and related compounds in higher plants. Part 16. Naphthoquinones from Radermachera sinica Hemsl. (Bignoniaceae). J Chem Soc Perkin Trans. 1981;1:2764–2770.
   Google Scholar
• Sanderman W, Simatupang MH, Wenderborn W. New quinones from the heartwood of Paratecoma peroba. Naturwiss. 1968;55:38.
   PubMed Web of Science ®Google Scholar
• Joshi KC, Bansal RK, Patni R. Chemical examination of the roots of Stereospermum suaveolens DC. J Ind Chem Soc. 1977;54:648–649.
   Web of Science ®Google Scholar
• Prakash L, Garg MG. Chemical constituents of the roots of Millingtonia hortensis Linn. and Acacia nilotica (Linn.) Del. J Ind Chem Soc. 1981;58:96–97.
   Web of Science ®Google Scholar
• Purushothaman KK, Natarajan RK. Chemical examination of Patala (Stereospermum tetragonum DC). J Res Ind Med. 1974;9:107–108.
   Google Scholar
• Chauhan AK, Dobhal MP, Uniyal PN. Phytochemical investigation of Catalpa longissima. Herba Pol. 1988;34:3–5.
   Google Scholar
• Duarte DS, Dolabela MF, Salas CE, et al. Chemical characterization and biological activity of Macfadyena unguis-cati (Bignoniaceae). J Pharm Pharmacol. 2000;52:347–352.
   PubMed Web of Science ®Google Scholar
• Lima CSA, De Amorim ELC, Nascimento SC, et al. Cytotoxic pyranonaphthoquinones from Melloa quadrivalvis (Bignoniaceae). Nat Prod Res. 2005;19:217–222.
   PubMed Web of Science ®Google Scholar
• Eyong KO, Krohn K, Hussain H, et al. Newbouldiaquinone and newbouldiamide: a new naphthoquinone-anthraquinone coupled pigment and a new ceramide from Newboldia laevis. Chem Pharm Bull. 2005;53:616–619.
   PubMed Web of Science ®Google Scholar
• Ravelo AG, Estevez-Braun A, Perez-Sacau E. The chemistry and biology of lapachol and related natural products α and β-lapachones. In: edited by, Rahman AU. Studies in natural products chemistry” (Bioactive Natural Products). The Netherlands: Elsevier Science Publishers; 2003. Vol. 29. 719–760.
   Google Scholar
• Zhang C, Qu Y, Jia Y, et al. α-Lapachol analog, its synthetic method and application as anticancer drug. CN105503692A. 2016.
   Google Scholar
• Vargas MD, Pinto AC, Camara CA, et al. Natural naphthoquinones and semi-synthetic, partially hydrogenated derivatives of lapachol with cytotoxic and antitumor activity. BR2005002766A. 2007.
   Google Scholar
• Xue M, Guo C, Guan W, et al. Application of lapachol in preparation of products for preventing and/or treating malignant glioma. CN103239430A. 2013.
   Google Scholar
• Cen S, Zhang Q, Mi Z, et al. Application of lapachol for producing HIV-1 virus-resisting medicine. CN102885802A. 2013. .
   Google Scholar
• Ashwell MA, Tandon M, Lapierre JM, et al. Novel lapachone compounds and methods of use thereof. US20090105166A1. 2009. .
   Google Scholar
• Ashwell M, Tandon M, Lapierre JM, et al. Novel lapachone compounds and methods of use thereof. WO2009051752A1. 2009.
   Google Scholar
• Li CJ, Li Y β-lapachone is a broad spectrum anti-cancer agent. US20050222246A1. 2005.
   Google Scholar
• Li CJ β-Lapachone and methods of treating cancer. US20050187288A1. 2005.
   Google Scholar
• Li CJ, Li Y Method of treatment of lung cancer. US20050197406A1. 2005.
   Google Scholar
• Li CJ Beta-lapachone and s-phase drug combinations for cancer treatment. WO2005082354A1. 2005.
   Google Scholar
• Li CJ, Li Y Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent. US20050197405A1. 2005.
   Google Scholar
• Li CJ, Li Y Method for the treatment of colon cancer. US20050192361A1. 2005.
   Google Scholar
• Li CJ, Li Y Method for the treatment of pancreatic cancer. US20050192360A1. 2005.
   Google Scholar
• Li CJ Combination cell cycle checkpoint activators for treating cancers. US20050192247A1. 2005.
   Google Scholar
• Pardee AB, Anderson K, Gupta D, et al. Method of treating hematologic tumors and cancers. US20030036515A1. 2003.
   Google Scholar
• Blokhin AV, Frydman B, Marton LJ, et al. Preparation of novel quinones as disease therapies. WO2000066528A2. 2000.
   Google Scholar
• Ashwell MA, Li CJ, Tandon M, et al. Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential. US20060034796A1. 2006.
   Google Scholar
• Frydman BJ, Witiak DT, Marton LJ, et al. Preparation of novel ortho-naphthoquinone derivatives and their use in the inhibition of neoplastic cell growth. WO9731936A2. 1997.
   Google Scholar
• Wipf P, Van-Houten B, Qian W, et al. Preparation of a mitochondrial targeted β-lapachone for treating cancer and neurodegeneration. WO2016200934A1. 2016.
   Google Scholar
• Pardee A, Li CJ Treatment of human prostate disease with beta-lapachone derivatives. WO9707797A1. 1997.
   Google Scholar
• Pardee A, Li CJ β-Lapachone derivatives for treatment of prostate cancer. WO9708162A1. 1997.
   Google Scholar
• Wang G, Hao H, Liu H, et al. NQO1 targeting drugs as NAD+ de novo synthesis inhibitors, and antitumor application thereof. CN104524579A. 2015.
   Google Scholar
• Wu L, Wang Y Preparation of β-Lapachol derivatives as antitumor agents. CN105541732A. 2016
   Google Scholar
• So HS, Kim HJ, Shen A Naphthoquinone compounds for preventing and treating pancreatitis. WO2016167622A2. 2016
   Google Scholar
• Kim HS, Park JS Lapachone for the prevention and treatment of degenerative brain diseases. KR2016081588A. 2016
   Google Scholar
• Yoo SK, Yoon JS, Park MG Naphthoquinone-based pharmaceutical composition for treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases. WO2008136642A1. 2008.
   Google Scholar
• Lee SY, Park SH, Kim SU, et al. Lapachone for treating and preventing nervous system disease. KR2014054527A. 2014.
   Google Scholar
• Lee SM, Hwang JS, Lee SM, et al. Lapachone for treating skin hyperpigmentation. KR2012062120A. 2012.
   Google Scholar
• Kim SU, Yoon SM, Choi JG Topical preparations containing β-lapachone for reducing skin wrinkles. KR2011115722A. 2011.
   Google Scholar
• Garkavtsev I, Jain RK Treatment of angiogenic- or vascular-associated diseases. US20140161720A1. 2014.
   Google Scholar
• Zhang C, Wu Z, Li S, et al. Streptomyces for manufacture of antibacterial antitumor agents. CN103421706A. 2013
   Google Scholar
• Li Q, Wang Z Application of 9-methoxy-α-lapachone in indole amine 2,3-dioxygenase-1 inhibitor. CN106074492A. 2016.
   Google Scholar
• Li Q, Wang Z Application of dehydro α-lapachol in indole amine 2,3-dioxygenase-1 inhibitor. CN106074491A. 2016.
   Google Scholar
• Shapiro GI, Cunningham CC. ARQ 501 in subjects with cancer (ARQ 501 in subjects with cancer) (NCT00075933). ClinTrials.gov. 2008b. Available from: http://clinicaltrials.gov/ct2/show/NCT00075933
   Google Scholar
• Cunningham CC. ARQ 501 in combination with docetaxel in patients with cancer (NCT00099190). ClinTrials.gov. 2008. http://www.clinicaltrials.gov/ct2/show/NCT00099190
   Google Scholar
• Shapiro G. An exploratory biomarker study of ARQ 501 in patients with advanced solid tumors (NCT00524524). ClinTrials.gov. 2008a. http://clinicaltrials.gov/ct2/show/NCT00524524
   Google Scholar
• Senzer NN. An extension study for patients previously treated with ARQ 501 (NCT00622063). ClinTrials.gov. 2008. http://www.clinicaltrials.gov/ct2/show/NCT00622063
   Google Scholar
• ArQule. ARQ 501 in combination with gemcitabine in subjects with pancreatic cancer (NCT00102700). ClinTrials.gov. 2008a. http://clinicaltrials.gov/ct2/show/NCT00102700
   Google Scholar
• ArQule. Safety and efficacy study of ARQ 501 in adult patients with leiomyosarcoma (NCT00310518). ClinTrials.gov. 2008b. Available from: http://clinicaltrials.gov/ct2/show/NCT00310518
   Google Scholar
• ArQule. A study of ARQ 501 in patients with squamous cell carcinoma of the head and neck (NCT00358930). ClinTrials.gov. 2008c. http://clinicaltrials.gov/ct2/show/NCT00358930
   Google Scholar
• Kim I, Kim H, Ro J, et al. Preclinical pharmacokinetic evaluation of β-lapachone: characteristics of oral bioavailability and first-pass metabolism in rats. Biomol Ther (Seoul). 2015;23:296–300.
   PubMed Web of Science ®Google Scholar
• Nasongkla N, Wiedmann AF, Bruening A, et al. Enhancement of solubility and bioavailability of β-lapachone using cyclodextrin inclusion complexes. Pharm Res. 2003;20:1626–1633.
   PubMed Web of Science ®Google Scholar
• Martins P, Jesus J, Santos S, et al. Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine’s tool box. Molecules. 2015;20:16852–16891.
   PubMed Web of Science ®Google Scholar
• Akhtar J, Khan AA, Ali Z, et al. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. Eur J Med Chem. 2017;125:143–189.
   PubMed Web of Science ®Google Scholar
• Silva EN Jr, Deus CF, Cavalcanti BC, et al. Synthesis and evaluation of quinonoid compounds against tumor cell lines. Eur J Med Chem. 2011;46:399–410.
   PubMed Web of Science ®Google Scholar
• Kumi-Diaka J, Saddler-Shawnette S, Aller A, et al. Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: therapeutic synergy in genistein and β-lapachone combination treatment. Cancer Cell Int. 2004;4:5.
   PubMed Web of Science ®Google Scholar